Determination of growth fraction in advanced prostate cancer by KI‐67 immunostaining and its relationship to the time to tumor progression after hormonal therapy

• Published in: Cancer Vol. 67; no. 12; pp. 3065 - 3071
• Main Authors: Sadi, Marcus V., Barrack, Evelyn R.
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 15.06.1991
• Subjects: Aged; Aged, 80 and over; Androgen Antagonists - therapeutic use; Antibodies, Monoclonal; Cell Cycle; Cell Nucleus - chemistry; Cell Nucleus - ultrastructure; Cytoplasm - chemistry; Cytoplasm - ultrastructure; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Metastasis; Probability; Prognosis; Prostatic Neoplasms - chemistry; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Prostatic Neoplasms - physiopathology; Receptors, Androgen - analysis; Staining and Labeling; Time Factors
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19910615)67:12<3065::AID-CNCR2820671222>3.0.CO;2-U

Reliable predictors of response for prostate cancer patients undergoing hormonal therapy are lacking. This study investigates the possibility that tumor proliferation rates might predict tumor behavior for these patients. The growth fraction of metastatic prostate cancer biopsy specimens obtained before androgen withdrawal therapy was evaluated by Ki‐67 antibody immunohistochemical study to determine whether a higher tumor growth fraction was associated with a shorter time to tumor progression after therapy. The percentage of Ki‐67‐positive malignant epithelial nuclei in the primary tumors of 17 patients ranged from 1.7% to 7.5% (median, 2.5%). When patients were divided into two response groups according to the median time to progression, poor responders (time to progression < 20 months) and good responders (≥ 20 months) had similar growth fractions (3.5 ± 0.5% versus 3.1 ± 0.6% Ki‐67‐positive nuclei, respectively). However, when patients were divided into two groups based on the median growth fraction, patients with a high growth fraction (> 2.5% Ki‐67‐positive nuclei) tended to have a shorter time to progression (median, 10 months) than patients with a low (< 2.5%) growth fraction (median time to progression, 25 months), although statistical significance was not reached. Despite this interesting trend, Ki‐67 immunostaining was not accurate to predict the time to progression in individual patients undergoing hormonal therapy. Reliable prediction of growth rates may require measurement of both cell proliferation and cell death rates.